# Galliprant Grapiprant Dose: EP4 Receptor Arthritis Dose Guide ## Key Takeaways - The FDA and EMA-approved dose for Galliprant (grapiprant) in dogs is 2 mg/kg, administered orally, once daily, for controlling osteoarthritis pain and inflammation. This dose is based on pharmacokinetic and clinical efficacy studies. - Grapiprant is a selective EP4 receptor antagonist, belonging to the piprant class, and differs from traditional NSAIDs by not inhibiting cyclooxygenase (COX) enzymes, potentially reducing gastrointestinal and renal side effects. - The 2 mg/kg dose was predicted through a translational approach involving comparative receptor binding affinity, serum protein binding, and effective doses in rat models, subsequently validated in canine clinical trials. - Pharmacokinetic studies show rapid absorption of grapiprant in dogs, with peak plasma concentrations typically reached within 1-2 hours, supporting its once-daily dosing regimen. - While effective for chronic osteoarthritis, grapiprant's analgesic effect may be less robust than traditional NSAIDs in models of intense, acute pain, suggesting a distinction in its clinical application for chronic versus acute pain management. - Grapiprant has demonstrated safety in MDR1-1Δ mutant collies at the labeled dosage, with only self-limiting vomiting reported in a small percentage of treated animals. --- **The definitive answer:** The FDA-approved and EMA-approved dose of Galliprant (grapiprant) for the control of pain and inflammation associated with osteoarthritis (OA) in dogs is **2 mg/kg, administered orally, once daily** [1][2]. This dose is based on extensive pharmacokinetic and clinical efficacy studies that established the drug's safety margin and therapeutic window. For pet owners, this means a 20 kg (44 lb) [dog](/knowledge/veterinary-medicine/clinical-methods/dog) would receive a 40 mg tablet once daily. Grapiprant is not a traditional NSAID; it belongs to the piprant class and works by selectively blocking the EP4 receptor, a specific target in the inflammatory pathway [1][2]. This guide provides a comprehensive, source-grounded review of grapiprant's pharmacology, dosing, clinical applications, and safety profile for veterinary professionals and informed pet owners. --- ## At a Glance: Grapiprant Dose and Key Facts | Parameter | Recommendation | | :--- | :--- | | **Active Ingredient** | Grapiprant (Galliprant®) | | **Drug Class** | Piprant (Selective EP4 receptor antagonist) | | **Approved Species** | Dogs | | **Approved Dose** | 2 mg/kg, orally, once daily [1][2] | | **Indication** | Control of pain and inflammation associated with osteoarthritis (OA) [1] | | **Mechanism of Action** | Selective antagonist of the EP4 prostaglandin E2 (PGE2) receptor [1] | | **Key Advantage** | Does not inhibit cyclooxygenase (COX) enzymes, potentially reducing GI and renal side effects associated with traditional NSAIDs [3][2] | | **Onset of Action** | Rapid absorption; peak plasma concentrations typically reached within 1-2 hours in dogs [4] | | **Regulatory Status** | FDA-approved (2016) and EMA-approved (2018) for canine OA [1][2] | --- ## Understanding Grapiprant and the EP4 Receptor To understand the dose and clinical utility of grapiprant, one must first appreciate its unique mechanism of action. Traditional non-steroidal anti-inflammatory drugs (NSAIDs) work by inhibiting cyclooxygenase (COX) enzymes, which are responsible for producing prostaglandins. While effective, this broad inhibition can lead to adverse effects, particularly in the gastrointestinal tract and kidneys [3]. Grapiprant represents a paradigm shift. It is the pioneer member of the piprant class and functions as a highly selective antagonist of the EP4 receptor, one of four receptor subtypes for prostaglandin E2 (PGE2) [1][2]. PGE2 is a potent pro-inflammatory mediator that contributes to pain and inflammation by binding to its receptors, including EP4 [1][5]. By specifically blocking the EP4 receptor, grapiprant interrupts the PGE2-mediated pain signaling pathway without affecting the production of other prostaglandins that are crucial for normal physiological functions like gastric mucosal protection and renal blood flow [1][3]. The EP4 receptor plays a significant role in mediating pain. Research has shown that PGE2-elicited nociception (the sensation of pain) is mediated through this receptor [1]. Furthermore, EP4 receptors are expressed by peripheral sensory neurons, making them a prime target for analgesic therapy [6]. Studies in animal models have confirmed that blocking EP4 receptors with selective antagonists like grapiprant reduces pain and inflammation [1][5][6]. In a rat model of adjuvant-induced arthritis, the EP4 antagonist CJ-023,423 (the research name for grapiprant) demonstrated significant inhibitory effects on paw swelling, inflammatory biomarkers, synovial inflammation, and bone destruction, comparable to a selective COX-2 inhibitor [5]. --- ## The Science Behind the 2 mg/kg Dose The 2 mg/kg dose was not chosen arbitrarily. It was the culmination of a rational drug development process that predicted the effective canine dose before clinical trials began. This process, detailed by Nagahisa and Okumura, involved a multi-step translational approach [1]. ### Dose Prediction and Clinical Validation The estimated canine efficacy dose was calculated based on several factors [1]: 1. **Comparative Receptor Binding Affinity:** The affinity of grapiprant for the EP4 receptor in dogs, rats, and humans was measured and compared. 2. **Serum Protein Binding:** The degree to which the drug binds to proteins in the blood, which affects the concentration of free (active) drug, was accounted for. 3. **Effective Doses in Rat Models:** The doses found to be effective in rat models of pain and inflammation were used as a reference point. 4. **Human Clinical Studies:** Data from human clinical trials investigating grapiprant's efficacy in OA were also incorporated. This analysis predicted an efficacy dose of between 1.3 and 1.7 mg/kg. This prediction guided the doses tested in a pilot study, and the results ultimately led to the approval of the commercial tablet dose of 2 mg/kg once daily for canine OA [1]. This dose was subsequently validated in clinical settings and is now the standard of care [2]. ### Pharmacokinetics: What the Body Does with Grapiprant Pharmacokinetic studies in dogs show that grapiprant is rapidly absorbed after oral administration. In a study of collies homozygous for the MDR1-1Δ mutation, the median time to maximum plasma concentration (Tmax) was 1 hour, with a maximum concentration (Cmax) of 5.2 μg/mL after the first dose [4]. This rapid absorption is beneficial for managing pain. The terminal half-life is relatively short, around 4.3 hours in that study, which supports the once-daily dosing regimen [4]. --- ## Clinical Use in Osteoarthritis Management Osteoarthritis (OA) is a chronic, degenerative joint disease characterized by pain, inflammation, and loss of mobility. It is one of the most common causes of chronic pain in dogs. Traditional management relies heavily on NSAIDs, but the potential for adverse effects, especially with long-term use, is a significant concern. Grapiprant offers a valuable alternative due to its targeted mechanism [3][2]. ### Efficacy in Acute and Chronic Pain Models Clinical studies have investigated grapiprant's efficacy in both acute and chronic pain settings. - **Acute Arthritis Model:** A study by García de Salazar Alcalá et al. compared the efficacy of grapiprant and firocoxib (Previcox®) in an induced model of acute arthritis in dogs. The study found that while firocoxib provided consistent pain control over 24 hours, the grapiprant-treated group showed significant lameness at 5, 7, and 10 hours post-arthritis induction (7, 9, and 12 hours post-treatment) [7]. This suggests that a single dose of grapiprant may have a shorter duration of action in an acute, severe pain model compared to firocoxib. - **Urate-Induced Synovitis:** Another study compared grapiprant (2 mg/kg) and carprofen (4.4 mg/kg) in a urate-induced synovitis model. Here, lameness scores for the grapiprant treatment remained significantly higher at 12 and 24 hours compared to baseline, while carprofen-treated dogs showed significantly lower lameness scores at 6, 12, and 24 hours [8]. This further indicates that grapiprant's analgesic effect may be less robust than traditional NSAIDs in models of intense, acute pain. - **Chronic Pain:** Despite the mixed results in acute pain models, grapiprant has shown efficacy in managing chronic OA pain. A narrative review by Sartini and Giorgi concluded that the therapeutic efficacy of grapiprant seems more suited to chronic rather than acute pain [2]. This is a crucial distinction for veterinarians when selecting an appropriate analgesic protocol. For chronic OA, grapiprant is a viable option, but for acute flare-ups or severe pain, a traditional NSAID might be more effective [7][8]. ### Grapiprant vs. Traditional NSAIDs The key difference lies in the mechanism of action. Traditional NSAIDs like carprofen, firocoxib, and meloxicam inhibit COX enzymes, reducing the production of all prostaglandins, including those that protect the gastric lining and maintain renal perfusion. Grapiprant, by selectively blocking only the EP4 receptor, leaves these protective pathways intact [1][3][2]. This "non-cyclooxygenase inhibiting" mechanism reduces the potential for adverse side effects associated with COX inhibition, making it a promising drug for long-term use [3]. --- ## Safety and Tolerance The safety profile of grapiprant has been evaluated in several studies, including in dogs with specific genetic sensitivities. ### Use in MDR1-1Δ Mutant Collies A critical study by Heit et al. investigated the tolerance and pharmacokinetics of Galliprant™ in collies homozygous for the MDR1-1Δ (multidrug resistance) mutation. These dogs are sensitive to many drugs, including ivermectin and various chemotherapeutic agents, because they lack a functional P-glycoprotein (P-gp) efflux pump. The study found that when administered at the labeled dosage of 2 mg/kg once daily for 28 days, grapiprant was well-tolerated. The only treatment-related clinical sign was self-limiting vomiting in 2 out of 8 treated animals, and one dog had a slight, transient decrease in serum albumin and total protein [4]. This suggests that grapiprant is safe for use in this breed, although the study noted that clearance from the central compartment was 71% less in collies than in beagles, indicating a potential breed difference in drug metabolism [4]. ### General Safety Profile Grapiprant's selective mechanism is designed to be safer for the gastrointestinal tract and kidneys. The absence of COX inhibition means that the production of cytoprotective prostaglandins in the stomach is not suppressed, which is a major advantage over traditional NSAIDs [3]. The most commonly reported side effect in clinical studies is vomiting, which is often self-limiting [4][2]. --- ## Grapiprant in Other Species: An Off-Label Perspective While grapiprant is only approved for use in dogs, its pharmacokinetics have been studied in other species, offering insights for potential off-label use in veterinary practice. - **Cats:** Studies have evaluated the pharmacokinetics of grapiprant after 2 mg/kg oral administration in cats [9]. A safety and toxicokinetic profile has also been established for daily oral administration in this species [10]. These studies provide foundational data, but grapiprant is not currently approved for feline use. - **Horses:** Research in horses has explored the pharmacokinetics and pharmacodynamics of grapiprant. One study administered a single oral dose of 15 mg/kg and found a short duration of EP4 receptor engagement, with significant TNF-alpha stimulation noted for only 2-4 hours post-administration [11]. Another study found that the approved canine dose of 2 mg/kg resulted in measurable but very brief plasma concentrations in horses, falling below the limit of quantification in most animals by 1-2 hours [12]. These findings suggest that the canine dose is not effective in horses and that higher or more frequent dosing would be required, which is not currently recommended. - **Pigs:** A study in juvenile pigs administered a 12 mg/kg oral dose and achieved plasma concentrations consistent with analgesia in dogs, suggesting this may be a starting point for further research in this species [13]. - **Non-Human Primates:** A 2025 study in rhesus macaques using the 2 mg/kg canine dose found that they absorbed grapiprant more slowly and at a lower level than dogs, with a Tmax of 2 hours and a Cmax of 23.8 ng/mL [3]. These studies highlight that species-specific differences in drug absorption and metabolism are significant. The canine dose of 2 mg/kg cannot be directly extrapolated to other species without further research. --- ## How to Administer Galliprant - **Dose:** The dose is 2 mg/kg (approximately 0.9 mg/lb) given orally once daily [1][2]. - **Administration:** It can be given with or without food. However, if your pet vomits when given the medication on an empty stomach, try giving it with a small meal. - **Duration:** Grapiprant is often used for long-term management of chronic OA. The duration of treatment should be determined by your veterinarian based on your dog's response and ongoing pain assessment. - **Missed Dose:** If you miss a dose, give it as soon as you remember. If it is almost time for the next dose, skip the missed dose and resume the normal schedule. Do not give a double dose. --- ## Limitations and When to Contact a Veterinarian This guide provides a comprehensive overview of grapiprant dosing and use, but it is educational and is not a substitute for veterinary diagnosis or treatment. Breed-level information, such as the MDR1-1Δ study, cannot predict the response of an individual animal. Every dog is unique, and a thorough physical examination and diagnostic workup by a veterinarian are essential to confirm a diagnosis of OA, rule out other causes of pain, and determine if grapiprant is the right choice for your pet. **Contact your veterinarian immediately if you observe any of the following:** - Vomiting, diarrhea (or diarrhoea), or loss of appetite that persists for more than 24 hours. - Signs of gastrointestinal bleeding, such as black, tarry stools or vomiting blood. - Changes in drinking or urinating habits. - Lethargy, weakness, or jaundice (yellowing of the gums or skin). - Any signs of an allergic reaction, such as hives, facial swelling, or difficulty breathing. Never administer grapiprant or any other medication to your pet without first consulting a veterinarian. Dosage errors or use in animals with underlying health conditions can be dangerous. --- ## The Clinical Rationale for Choosing Grapiprant in Canine Osteoarthritis Osteoarthritis is not a single disease process but a final common pathway of joint failure that results from an imbalance between degradative and reparative processes within articular cartilage, subchondral bone, and synovium. The pain experienced by dogs with OA is complex and multifactorial, involving both nociceptive and neuropathic components. Understanding this complexity is essential for appreciating where grapiprant fits within a multimodal analgesic plan. The EP4 receptor is one of four G-protein-coupled receptors (EP1, EP2, EP3, and EP4) through which prostaglandin E2 (PGE2) exerts its effects. While all four receptors are involved in various aspects of inflammation and pain, EP4 has emerged as a particularly attractive therapeutic target for several reasons. First, EP4 is highly expressed in the synovium of arthritic joints, where it contributes to the production of matrix metalloproteinases and other degradative enzymes that erode cartilage [1]. Second, EP4 activation sensitizes peripheral nociceptors, lowering their threshold for activation and contributing to the allodynia and hyperalgesia that characterize chronic OA pain [6]. Third, EP4 signaling promotes angiogenesis and osteoclast activation, both of which contribute to the structural progression of OA [5]. Traditional NSAIDs, by inhibiting COX-1 and COX-2, reduce the synthesis of all prostaglandins, including PGE2, but they also reduce prostacyclin (PGI2) and other prostaglandins that are cytoprotective in the gastric mucosa and important for maintaining renal blood flow during periods of hypotension or dehydration [3]. The clinical consequence of this broad inhibition is a well-documented risk of gastrointestinal ulceration, renal papillary necrosis, and hepatotoxicity, particularly in older dogs or those with concurrent disease. Grapiprant circumvents these risks by leaving prostaglandin synthesis intact and instead blocking the downstream signaling of PGE2 through a single receptor subtype [1][2]. This mechanistic distinction has practical implications for patient selection. A dog with well-compensated chronic kidney disease, for example, may tolerate grapiprant better than a traditional NSAID because renal perfusion is maintained. Similarly, a dog with a history of gastrointestinal upset on other NSAIDs may be a candidate for a trial of grapiprant. However, it is critical to emphasize that grapiprant is not risk-free, and its safety in dogs with pre-existing renal or hepatic disease has not been definitively established in large-scale clinical trials. The decision to use grapiprant in such patients should be made on a case-by-case basis, with appropriate monitoring and owner education. ## Diagnostic Workflow: Confirming Osteoarthritis Before Prescribing The decision to prescribe grapiprant should never be made based on signalment and owner history alone. A thorough diagnostic workup is essential to confirm that OA is indeed the source of the patient's pain and to rule out other conditions that may mimic or coexist with OA, such as immune-mediated polyarthritis, infectious arthritis, neoplasia, or neurologic disease. The diagnostic approach typically begins with a complete orthopedic examination. This should include observation of the dog's gait at a walk and trot, assessment of weight-bearing, and palpation of each joint for effusion, thickening, crepitus, and pain on manipulation. Range of motion should be assessed and compared between contralateral limbs. It is important to remember that bilateral disease is common in canine OA, and a dog may present with lameness in one limb while having clinically silent disease in the contralateral joint. A thorough examination will identify these subclinical cases, which may influence the decision to initiate therapy. Radiography remains the cornerstone of OA diagnosis in practice. Standard views should include orthogonal projections of the affected joint, and contralateral views are recommended for comparison. Classic radiographic findings of OA include joint effusion, periarticular osteophyte formation, subchondral bone sclerosis, and, in advanced cases, subchondral bone cysts and joint space narrowing. However, it is essential to recognize that radiographic changes do not always correlate with the degree of pain or lameness. A dog with minimal radiographic changes may be severely lame, while another with dramatic radiographic changes may be relatively comfortable. This dissociation underscores the importance of clinical assessment in guiding treatment decisions. In some cases, additional diagnostics may be warranted. Arthrocentesis with synovial fluid analysis is indicated if inflammatory or septic arthritis is suspected. Advanced imaging, such as computed tomography or magnetic resonance imaging, may be useful for evaluating complex joints like the elbow or stifle, or for surgical planning. However, for the majority of dogs presenting with typical clinical signs and radiographic findings, a diagnosis of OA can be made with confidence, and medical management can be initiated. Once the diagnosis is confirmed, baseline blood work is recommended before starting any long-term anti-inflammatory therapy. A complete blood count, serum biochemistry profile, and urinalysis provide valuable information about the patient's overall health and help identify subclinical disease that might influence drug selection or dosing. For older dogs, a baseline assessment of renal and hepatic function is particularly important, as these organ systems are common sites of adverse drug effects. ## Owner Observation: Recognizing Pain and Monitoring Response The success of any OA management plan depends heavily on the owner's ability to recognize pain and monitor the dog's response to therapy. Many owners mistakenly believe that a dog that is eating, drinking, and wagging its tail cannot be in significant pain. In reality, dogs are stoic by nature and often mask pain until it becomes severe. Veterinarians should take time to educate owners about the subtle signs of chronic pain in dogs. Common behavioral changes associated with OA include reluctance to jump onto furniture or into the car, difficulty rising after rest, stiffness that improves with movement, reduced interest in walks or play, decreased interaction with family members, and changes in posture or gait. Some dogs become irritable or aggressive when touched, particularly around affected joints. Others may show changes in sleeping patterns, such as sleeping more during the day or being restless at night. House soiling can occur if the dog is reluctant to navigate stairs or slippery floors to reach the door. Owners should be encouraged to keep a simple daily log of their dog's activity level, mobility, and demeanor. This log can be invaluable during follow-up visits, as it provides objective data about the dog's response to treatment. Several validated owner-completed questionnaires exist for assessing canine OA pain, and while these are primarily used in research settings, simplified versions can be adapted for clinical practice. Asking owners to rate their dog's mobility on a scale of 0 to 10, where 0 is normal and 10 is non-weight-bearing lame, can provide a useful baseline and track changes over time. When grapiprant is prescribed, owners should be advised that the full therapeutic effect may not be apparent immediately. While the drug is rapidly absorbed, with peak plasma concentrations reached within 1 to 2 hours, the clinical response in chronic OA may take several days of daily dosing to become evident [4]. Owners should be encouraged to give the medication consistently at the same time each day and to observe their dog for any changes in activity or comfort. If there is no improvement after 7 to 14 days of daily dosing, the veterinarian should be contacted to reassess the treatment plan. ## Preparing for the Veterinary Visit: What Owners Should Bring A well-prepared owner can significantly enhance the efficiency and effectiveness of a veterinary consultation for suspected OA. Veterinarians should provide owners with a checklist of information to bring to the appointment, which can be communicated verbally or through a written handout. Owners should be asked to bring a complete list of all medications and supplements their dog is currently receiving, including prescription drugs, over-the-counter products, and herbal or nutraceutical preparations. This information is critical for assessing potential drug interactions. For example, the concurrent use of grapiprant with corticosteroids or other NSAIDs is contraindicated due to the increased risk of gastrointestinal ulceration. Similarly, the use of grapiprant with certain supplements, such as high-dose fish oil or other anti-inflammatory agents, may have additive effects that could increase the risk of bleeding, although this has not been specifically studied. A video recording of the dog moving at home can be extremely helpful, as dogs often move differently in the clinic than they do in their familiar environment. Owners should be encouraged to record their dog walking and trotting on a level surface, as well as navigating stairs if possible. This footage can reveal subtle lameness that may not be apparent during the in-clinic examination. Owners should also be prepared to answer questions about their dog's history, including when the signs first began, whether they have been progressive or intermittent, and what factors seem to worsen or improve the signs. Questions about appetite, thirst, urination, and defecation are important for assessing overall health and identifying potential contraindications to therapy. A history of vomiting, diarrhea, or changes in stool color may indicate gastrointestinal disease that could influence drug selection. Finally, owners should be encouraged to write down any questions they have before the visit. This ensures that their concerns are addressed and reduces the likelihood of forgetting important points during the consultation. Common questions include: How long will my dog need to take this medication? What are the potential side effects? Are there any alternatives? How will we know if the treatment is working? What should I do if my dog seems worse? ## Evidence Limitations and Gaps in Current Knowledge While the evidence base for grapiprant is substantial, it is important to acknowledge the limitations of the available data. Most clinical studies have been industry-sponsored and have focused on relatively short-term outcomes, typically 28 days. The long-term safety and efficacy of grapiprant over months or years of continuous use have not been definitively established. This is a significant gap, as OA is a chronic, progressive condition that typically requires lifelong management. The acute pain studies discussed earlier highlight another limitation. In the induced acute arthritis model, grapiprant provided less consistent pain control than firocoxib, with significant lameness noted at several time points [7]. Similarly, in the urate-induced synovitis model, grapiprant-treated dogs had higher lameness scores at 12 and 24 hours compared to carprofen-treated dogs [8]. These findings suggest that grapiprant may not be the ideal first-line choice for managing acute flare-ups of OA or for providing rapid, robust analgesia in the immediate postoperative period. However, it is important to note that these models induce intense, acute pain that may not accurately reflect the clinical scenario of chronic OA, where the pain is typically more moderate and constant. The comparative efficacy of grapiprant versus other NSAIDs in chronic OA has not been extensively studied in head-to-head trials. Most studies have compared grapiprant to placebo or have used non-inferiority designs. While the available evidence supports grapiprant's efficacy, it does not definitively establish that it is as effective as, or more effective than, traditional NSAIDs for all patients. Clinical experience suggests that individual dogs may respond differently to different drugs, and a dog that does not respond adequately to one NSAID may respond well to another. This variability underscores the importance of individualized treatment planning and regular reassessment. Another gap in the evidence base concerns the use of grapiprant in combination with other analgesics. Many dogs with moderate to severe OA require multimodal therapy, which may include gabapentin, amantadine, or other adjunctive medications. The safety and efficacy of grapiprant in combination with these drugs have not been specifically studied. While there is no theoretical reason to expect adverse interactions, the absence of data means that such combinations should be used with caution and careful monitoring. Finally, the pharmacokinetic data in special populations are limited. The study in MDR1-1Δ mutant collies found that clearance from the central compartment was 71% less in collies than in beagles, suggesting a potential breed difference in drug metabolism [4]. The clinical significance of this finding is unclear, as the drug was well-tolerated at the labeled dose in this study. However, it raises the question of whether other breeds may also metabolize grapiprant differently, and whether dose adjustments might be needed in certain populations. Similarly, the pharmacokinetics of grapiprant in very young or very old dogs, or in dogs with hepatic or renal impairment, have not been specifically studied. ## Prevention and Long-Term Management of Canine Osteoarthritis While grapiprant is an effective tool for managing the pain and inflammation of OA, it is not a cure, and it should be viewed as one component of a comprehensive, multimodal management plan. Prevention of OA is not always possible, particularly in dogs with genetic predispositions or traumatic joint injuries, but several strategies can reduce the risk or slow the progression of the disease. Weight management is arguably the single most important intervention in both the prevention and management of OA. Adipose tissue is metabolically active and produces pro-inflammatory cytokines, including tumor necrosis factor-alpha and interleukin-6, which contribute to systemic inflammation and may exacerbate joint disease. Furthermore, excess body weight increases the mechanical load on weight-bearing joints, accelerating cartilage degradation. Maintaining a lean body condition score is essential for all dogs, but particularly for those at risk for OA. For overweight dogs, a structured weight loss program that combines caloric restriction with controlled exercise is recommended. Nutritional supplementation may also play a role in joint health. Omega-3 fatty acids, particularly eicosapentaenoic acid and docosahexaenoic acid, have anti-inflammatory properties and have been shown to improve clinical signs in dogs with OA. These are often included in therapeutic joint diets or provided as supplements. Other nutraceuticals, such as glucosamine and chondroitin sulfate, are commonly used, although the evidence for their efficacy is mixed. These supplements are generally safe and may provide benefit in some dogs, but they should not be considered a substitute for evidence-based pharmacologic therapy. Physical rehabilitation and controlled exercise are important components of OA management. Regular, low-impact exercise, such as walking on soft surfaces or swimming, helps maintain muscle mass, joint mobility, and cardiovascular fitness. Muscle strengthening is particularly important, as strong muscles help stabilize joints and reduce the load on articular cartilage. A certified canine rehabilitation therapist can design a tailored exercise program that addresses the individual dog's needs and limitations. Physical modalities, such as therapeutic ultrasound, laser therapy, and extracorporeal shockwave therapy, may also provide pain relief and improve function in some dogs. Environmental modifications can significantly improve the quality of life for dogs with OA. Providing ramps or steps to help dogs access furniture, vehicles, or elevated surfaces reduces the need for jumping, which places significant stress on arthritic joints. Non-slip flooring, such as area rugs or yoga mats, can help dogs navigate slippery surfaces more confidently. Orthopedic beds provide supportive cushioning for painful joints and can improve sleep quality. Keeping the dog's nails trimmed is also important, as long nails can alter gait and increase the risk of slipping. Regular veterinary rechecks are essential for monitoring the progression of OA and adjusting the treatment plan as needed. The frequency of rechecks will depend on the severity of the disease and the stability of the dog's clinical signs. At each recheck, the veterinarian should perform a physical and orthopedic examination, review the owner's observations, and assess the dog's response to therapy. Blood work may be recommended periodically to monitor organ function, particularly in dogs on long-term anti-inflammatory therapy. ## Prognosis and Quality of Life Considerations The prognosis for a dog diagnosed with OA is generally good, provided the condition is managed appropriately. OA is a progressive disease, and while it cannot be reversed, its progression can be slowed, and its clinical signs can be effectively managed in most dogs. The goal of treatment is not to cure the disease but to maintain the dog's quality of life, preserve mobility, and minimize pain. The response to grapiprant is variable. Some dogs will experience significant improvement in mobility and comfort within the first week of treatment, while others may show a more gradual response. If there is no improvement after 14 days of daily dosing, the veterinarian should be consulted to discuss alternative or adjunctive therapies. It is not uncommon for dogs to require adjustments to their treatment plan over time, as the disease progresses or as the dog's response to a particular drug changes. Quality of life assessment is an important aspect of long-term management. Owners should be encouraged to think about what activities are important to their dog and to monitor whether the dog is still able to engage in those activities. A dog that is no longer able to enjoy walks, play with toys, or interact with family members may have a diminished quality of life, even if it is not showing obvious signs of pain. Open communication between the owner and veterinarian is essential for making informed decisions about treatment adjustments and, ultimately, about end-of-life care. It is also important to recognize that OA is often one of several comorbidities in older dogs. Chronic kidney disease, heart disease, endocrine disorders, and cognitive dysfunction are common in the geriatric population, and these conditions can interact with OA in complex ways. A dog with chronic kidney disease may be more susceptible to the renal effects of traditional NSAIDs, making grapiprant an attractive alternative. Conversely, a dog with heart disease may be on medications that interact with anti-inflammatory drugs. A comprehensive approach that addresses all of the dog's health issues is essential for optimizing outcomes. ## Special Population Considerations ### Geriatric Dogs Geriatric dogs represent the largest population of OA patients, and they present unique challenges for pain management. Age-related changes in organ function, particularly in the kidneys and liver, can affect drug metabolism and excretion. The safety of grapiprant in dogs with impaired renal or hepatic function has not been specifically studied, and caution is warranted. Baseline blood work and urinalysis are recommended before initiating therapy, and periodic monitoring is advised for dogs on long-term treatment. Geriatric dogs are also more likely to be on multiple medications for concurrent conditions, increasing the risk of drug interactions. A thorough medication history is essential, and the veterinarian should be consulted before adding any new medication or supplement. Cognitive dysfunction syndrome, which affects many older dogs, can complicate pain assessment, as affected dogs may not communicate pain in typical ways. Owners may misinterpret signs of pain, such as restlessness or vocalization, as behavioral issues related to cognitive decline. ### Dogs with Gastrointestinal Disease Dogs with a history of gastrointestinal disease, such as inflammatory bowel disease, pancreatitis, or previous NSAID-induced ulceration, are at increased risk for adverse effects from anti-inflammatory therapy. While grapiprant's mechanism of action suggests a lower risk of gastrointestinal ulceration compared to traditional NSAIDs, it is not without risk. Vomiting was the most commonly reported adverse effect in clinical studies [4][2]. In dogs with pre-existing gastrointestinal disease, grapiprant should be used with caution, and owners should be advised to monitor for signs of gastrointestinal upset, such as vomiting, diarrhea, or decreased appetite. If these signs occur, the medication should be discontinued, and the veterinarian should be consulted. ### Dogs with Renal or Hepatic Disease The use of grapiprant in dogs with renal or hepatic disease is a topic of ongoing discussion. The drug's selective mechanism, which does not inhibit COX enzymes, theoretically preserves renal blood flow and is less likely to cause the renal papillary necrosis associated with traditional NSAIDs. However, this theoretical advantage has not been confirmed in clinical trials involving dogs with pre-existing renal disease. Similarly, the hepatic metabolism of grapiprant means that dogs with liver disease may metabolize the drug differently, potentially leading to increased drug exposure and a higher risk of adverse effects. Until more data are available, grapiprant should be used with caution in these patients, with close monitoring and regular blood work. ### Young Dogs Osteoarthritis is less common in young dogs, but it can occur secondary to developmental orthopedic conditions such as hip dysplasia, elbow dysplasia, or osteochondritis dissecans. The safety of grapiprant in growing puppies has not been specifically studied. While the drug's mechanism of action does not suggest a specific risk to growing cartilage, the absence of data means that caution is warranted. In young dogs, the underlying developmental condition should be addressed, and pain management should be tailored to the individual patient. ### Cats and Other Species As discussed earlier, grapiprant is not approved for use in cats, and its use in this species is considered off-label. While pharmacokinetic and safety studies have been conducted in cats, the drug has not been approved for feline use, and its efficacy in feline OA has not been established [9][10]. Similarly, studies in horses have shown that the canine dose of 2 mg/kg results in very brief plasma concentrations, suggesting that this dose is not effective in horses [11][12]. Higher doses have been studied experimentally, but grapiprant is not approved for use in horses, and its use in this species should be considered experimental. The same caution applies to other species, including pigs and non-human primates, where pharmacokinetic studies have been conducted but clinical efficacy and safety have not been established [3][13]. ## Integrating Grapiprant into a Multimodal Pain Management Plan The most effective approach to managing canine OA is a multimodal one that combines pharmacologic and non-pharmacologic interventions. Grapiprant can be a valuable component of this approach, but it should not be used in isolation. A comprehensive plan should address weight management, exercise, nutrition, environmental modifications, and, when appropriate, adjunctive medications. For dogs with mild OA, grapiprant may be sufficient as a sole therapy, particularly when combined with weight management and controlled exercise. For dogs with moderate OA, a combination of grapiprant and adjunctive medications, such as gabapentin or amantadine, may be more effective than either drug alone. Gabapentin is commonly used for neuropathic pain, which can be a component of chronic OA pain, while amantadine is an NMDA receptor antagonist that may help prevent central sensitization. The use of these drugs in combination with grapiprant has not been specifically studied, but there is no theoretical reason to expect adverse interactions. For dogs with severe OA or those experiencing acute flare-ups, a traditional NSAID may be more appropriate than grapiprant, based on the available evidence from acute pain models [7][8]. In such cases, a short course of a traditional NSAID may be used to gain control of the pain, followed by a transition to grapiprant for long-term maintenance. This approach allows the dog to benefit from the rapid, robust analgesia of a traditional NSAID during the acute phase while minimizing the long-term risks associated with COX inhibition. It is also important to consider the use of other analgesic modalities, such as intra-articular injections of corticosteroids or hyaluronic acid, which can provide targeted relief for individual joints. These procedures should be performed by a veterinarian with appropriate training and experience. In some cases, surgical intervention, such as total hip replacement or arthroscopy, may be indicated for dogs with severe, refractory OA. ## Monitoring and Follow-Up Regular monitoring is essential for dogs on long-term grapiprant therapy. The frequency of monitoring will depend on the individual patient and the severity of the disease. For most dogs, a recheck examination every 3 to 6 months is appropriate. At each recheck, the veterinarian should assess the dog's response to therapy, perform a physical and orthopedic examination, and review the owner's observations. Blood work may be recommended periodically to monitor organ function, particularly in older dogs or those with concurrent disease. Owners should be educated about the signs of adverse drug reactions and instructed to contact the veterinarian immediately if any of these signs occur. The most common adverse effect is vomiting, which is often self-limiting [4][2]. However, persistent vomiting, diarrhea, loss of appetite, lethargy, or changes in drinking or urinating habits warrant immediate veterinary attention. Signs of gastrointestinal bleeding, such as black, tarry stools or vomiting blood, are a medical emergency and require immediate care. The decision to continue, adjust, or discontinue grapiprant therapy should be made collaboratively between the veterinarian and the owner, based on the dog's response to treatment and any adverse effects observed. Some dogs may require a dose adjustment, although the labeled dose of 2 mg/kg once daily is the only dose that has been approved [1][2]. There is no evidence to support dose escalation beyond the labeled dose, and doing so may increase the risk of adverse effects without providing additional benefit. ## Conclusion Grapiprant represents a significant advancement in the management of canine osteoarthritis. Its selective antagonism of the EP4 receptor provides effective pain relief while potentially reducing the risk of adverse effects associated with traditional NSAIDs [1][3][2]. The approved dose of 2 mg/kg once daily is well-supported by pharmacokinetic and clinical efficacy studies [1][2]. However, grapiprant is not a panacea, and its use should be guided by a thorough diagnostic workup, careful patient selection, and ongoing monitoring. By integrating grapiprant into a comprehensive, multimodal management plan, veterinarians can help dogs with OA maintain their mobility, comfort, and quality of life. ## Frequently Asked Questions ### What is the exact dose of Galliprant (grapiprant) for dogs? The exact FDA-approved and EMA-approved dose of Galliprant (grapiprant) for controlling pain and inflammation associated with osteoarthritis in dogs is 2 mg/kg, administered orally, once daily [1][2]. ### How does grapiprant work to relieve arthritis pain in dogs? Grapiprant works by selectively blocking the EP4 receptor, a specific target for the inflammatory mediator prostaglandin E2 (PGE2), thereby reducing pain and inflammation without inhibiting cyclooxygenase (COX) enzymes [1][2]. ### Is Galliprant a non-steroidal anti-inflammatory drug (NSAID)? Grapiprant is often grouped with NSAIDs for its anti-inflammatory effects, but it is technically a piprant, not a traditional NSAID, because it does not inhibit COX enzymes [1][3][2]. ### Can I give my dog Galliprant with other pain medications? You should never give your dog grapiprant with other NSAIDs or corticosteroids without explicit approval from your veterinarian, as this can increase the risk of serious adverse effects. ### What are the most common side effects of grapiprant in dogs? The most common side effect reported in clinical studies is self-limiting vomiting [4][2]. Other potential side effects may include diarrhea (or diarrhoea) and decreased appetite. ### How quickly does Galliprant start working in dogs? Grapiprant is rapidly absorbed after oral administration, with peak plasma concentrations typically reached within 1 to 2 hours in dogs [4]. However, the full therapeutic effect may take a few days of daily dosing to become apparent. ### Is grapiprant safe for dogs with kidney or liver disease? The safety of grapiprant in dogs with severe kidney or liver disease has not been fully established. While its mechanism suggests it may be safer than traditional NSAIDs, it should be used with caution and under close veterinary supervision in these patients. ### Is Galliprant safe to use in cats? Grapiprant is not FDA-approved for use in cats. While some pharmacokinetic and safety studies have been conducted in cats, it is considered an off-label medication and should only be used under the direct guidance of a veterinarian [9][10]. ## Sources [1] [Pharmacology of grapiprant, a novel EP4 antagonist: receptor binding, efficacy in a rodent postoperative pain model, and a dose estimation for controlling pain in dogs](https://www.semanticscholar.org/paper/56cb9b18cd59549e696560207a79a14963cebe1a) [2] [Grapiprant: A snapshot of the current knowledge](https://www.semanticscholar.org/paper/146074deb7d50744764701b79bfb04b7e36fb600) [3] [Single-Dose Pharmacokinetics of Grapiprant in Rhesus Macaques (Macaca mulatta)](https://www.semanticscholar.org/paper/f0e6dc2391690a60dfeefd2a40145ce4dad544d2) [4] [Tolerance and Pharmacokinetics of Galliprant™ Administered Orally to Collies Homozygous for MDR1‐1Δ](https://www.semanticscholar.org/paper/c2fdcee9fbe822c92609f8b3a7122f953e0ff1af) [5] [Effects of the selective EP4 antagonist, CJ-023,423 on chronic inflammation and bone destruction in rat adjuvant-induced arthritis.](https://pubmed.ncbi.nlm.nih.gov/18498708/) [6] [CJ-023,423, a novel, potent and selective prostaglandin EP4 receptor antagonist with antihyperalgesic properties.](https://pubmed.ncbi.nlm.nih.gov/17495127/) [7] [Assessment of the efficacy of firocoxib (Previcox®) and grapiprant (Galliprant®) in an induced model of acute arthritis in dogs](https://www.semanticscholar.org/paper/adcaba43f860ec68f1f02d6db38cdd96692d9112) [8] [Comparison of two inhibitors of E-type prostanoid receptor four and carprofen in dogs with experimentally induced acute synovitis.](https://www.semanticscholar.org/paper/eaa65dcf2533d72ce1d9881d546904cd5e19e2d1) [9] [Pharmacokinetics of grapiprant, a selective EP4 prostaglandin PGE2 receptor antagonist, after 2 mg/kg oral and i.v. administrations in cats](https://www.semanticscholar.org/paper/f4fb11595a965f3e949d272d2f78103feb56688b) [10] [Safety and toxicokinetic profiles associated with daily oral administration of grapiprant, a selective antagonist of the prostaglandin E2 EP4 receptor, to cats.](https://www.semanticscholar.org/paper/b9cee0f33dae2d6432a60067fc3b86d19efae260) [11] [Pharmacokinetics of grapiprant and effects on TNF-alpha concentrations following oral administration to horses](https://www.semanticscholar.org/paper/043255df222e78cd8581ab8290d2e4c7ce9b558d) [12] [Determination of grapiprant plasma and urine concentrations in horses.](https://www.semanticscholar.org/paper/63a3b1e7f9c734aeaa51ba06ad4a128acf68fbb3) [13] [Pharmacokinetics of a single oral dose of grapiprant in juvenile pigs (Sus scrofa domestica).](https://www.semanticscholar.org/paper/05503bdbbaf3c99d48b006ad8dd4694d10315f3e) [14] [Correction to: Assessment of the efficacy of firocoxib (Previcox®) and grapiprant (Galliprant®) in an induced model of acute arthritis in dogs](https://www.semanticscholar.org/paper/8e3046dc8f33a325c9ca4108e51be51229d970da) [15] [A phase I dose-escalation and expansion study of RMX1002, a selective E-type prostanoid receptor 4 antagonist, as monotherapy and in combination with anti-PD-1 antibody in advanced solid tumors](https://www.semanticscholar.org/paper/d1bad48f92460f7a54fffd729d45bce2351c6c1c) [16] [Prostanoid EP4 Receptor-Mediated Augmentation of I (h) Currents in Aβ Dorsal Root Ganglion Neurons Underlies Neuropathic Pain.](https://pubmed.ncbi.nlm.nih.gov/30409832/) [17] [Characterization of binding affinity of CJ-023,423 for human prostanoid EP4 receptor.](https://pubmed.ncbi.nlm.nih.gov/18408415/) [18] [Discovery of AAT-008, a novel, potent, and selective prostaglandin EP4 receptor antagonist.](https://www.semanticscholar.org/paper/a79fd343cab1fab13a76db7485ca6c2d5fe0f3a0) [19] [Osteoarthritis beim Hund – Grapiprant als neue Therapieoption](https://www.semanticscholar.org/paper/b574b55e05ee3ae6bdb46ec0725e364c9721a54a) [20] [A selective antagonist of prostaglandin E receptor subtype 4 attenuates abdominal aortic aneurysm.](https://pubmed.ncbi.nlm.nih.gov/30230255/)
## Related Clinical & Scientific Guides * [Drontal Plus Dewormer: Broad-Spectrum Dose Guide by Weight](/knowledge/veterinary-medicine/calculators-clinical-tools/drontal-plus-dewormer-broad-spectrum-dose-guide-by-weight) * [Panacur Fenbendazole Dewormer: Dog Fecal Parasite Treatment Schedule](/knowledge/veterinary-medicine/calculators-clinical-tools/panacur-fenbendazole-dewormer-dog-fecal-parasite-treatment-schedule) * [Prednisolone for Cats: Feline Safe Steroid Dose and Autoimmune](/knowledge/veterinary-medicine/calculators-clinical-tools/prednisolone-for-cats-feline-safe-steroid-dose-and-autoimmune)